A Zhengzhou Normal University study found that a ChatGPT-based depression screening tool, BDI-FS-GPT, achieved 89.3% sensitivity, outperforming the widely used PHQ-9 questionnaire, though researchers caution larger trials are still needed.
Mount Sinai has embedded OpenEvidence's AI clinical decision support tool directly into its Epic health record, letting physicians, nurses and pharmacists across seven hospitals query peer-reviewed medical evidence in natural language without leaving the patient chart.
A new market report details how Cleveland Clinic and Mayo Clinic have expanded AI enterprise-wide across outpatient surgery — from predictive risk models to post-discharge monitoring — as investors pour hundreds of millions into surgical AI startups.
Samsung Research disclosed two new on-device AI foundation models, xMAE and HiMAE, that analyze wearable heart, sleep and activity biosignals locally on a smartwatch without cloud processing, though both remain research projects without a release date.
Johns Hopkins researchers reported July 31, 2026 that their AI-powered DELFI liquid biopsy blood test detected liver cancer consistently across 377 patients from Guatemala and Romania, two populations with very different disease pathways.
A whistleblower lawsuit filed July 6, 2026 alleges Mayo Clinic staff concealed a 67% error rate in its internally built AI assistant MAYA and retaliated against the former research operations director who raised the concern.
MMRO announced September 4, 2026 that it earned URAC's Artificial Intelligence in Health Care Accreditation, becoming one of the first independent medical review organizations certified under the year-old voluntary AI governance program.
A Florida hospital faces a lawsuit alleging an AI diagnostic tool's low-risk flag delayed a patient's cancer diagnosis, raising new liability questions for hospitals and vendors deploying clinical AI tools.
Chai Discovery closed a $400 million Series C at a $3.8 billion valuation, tripling its price tag in seven months, as OpenAI, Eli Lilly, and Index Ventures back its AI-driven antibody design platform.
Germany's nationwide PRAIM study found AI-assisted mammogram reading raised the breast-cancer detection rate by 17.6%, adding to a wave of 2026 studies from Sweden and South Korea supporting AI as a screening aid.